Equities

AxoGen Inc

AxoGen Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)13.18
  • Today's Change0.08 / 0.61%
  • Shares traded77.40k
  • 1 Year change+123.39%
  • Beta1.0581
Data delayed at least 15 minutes, as of Nov 22 2024 17:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AxoGen Inc grew revenues 14.74% from 138.58m to 159.01m while net income improved from a loss of 28.95m to a smaller loss of 21.72m.
Gross margin76.13%
Net profit margin-7.91%
Operating margin-4.70%
Return on assets-7.40%
Return on equity-14.51%
Return on investment-8.49%
More ▼

Cash flow in USDView more

In 2023, AxoGen Inc increased its cash reserves by 71.93%, or 15.49m. Cash Flow from Investing totalled 19.25m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.72m for operations while cash generated from financing totalled 1.95m.
Cash flow per share-0.1689
Price/Cash flow per share--
Book value per share2.26
Tangible book value per share2.14
More ▼

Balance sheet in USDView more

AxoGen Inc has a Debt to Total Capital ratio of 32.24%, a lower figure than the previous year's 47.43%.
Current ratio3.74
Quick ratio2.47
Total debt/total equity0.4757
Total debt/total capital0.3224
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.